103 related articles for article (PubMed ID: 31911180)
1. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
[TBL] [Abstract][Full Text] [Related]
2. Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.
Dent P; Booth L; Poklepovic A; Martinez J; Hoff DV; Hancock JF
J Cell Physiol; 2020 Nov; 235(11):7889-7899. PubMed ID: 31912905
[TBL] [Abstract][Full Text] [Related]
3. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
[TBL] [Abstract][Full Text] [Related]
4. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
[TBL] [Abstract][Full Text] [Related]
5. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
[TBL] [Abstract][Full Text] [Related]
6. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
[TBL] [Abstract][Full Text] [Related]
8. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Booth L; Poklepovic A; Dent P
Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
[TBL] [Abstract][Full Text] [Related]
9. Neratinib augments the lethality of [regorafenib + sildenafil].
Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
[TBL] [Abstract][Full Text] [Related]
10. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
Liles JS; Arnoletti JP; Tzeng CW; Howard JH; Kossenkov AV; Kulesza P; Heslin MJ; Frolov A
Cancer Biol Ther; 2010 Sep; 10(6):555-63. PubMed ID: 20647770
[TBL] [Abstract][Full Text] [Related]
11. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
13. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
14. p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.
Axelrod MJ; Gordon V; Mendez RE; Leimgruber SS; Conaway MR; Sharlow ER; Jameson MJ; Gioeli DG; Weber MJ
Cell Signal; 2014 Aug; 26(8):1627-35. PubMed ID: 24662264
[TBL] [Abstract][Full Text] [Related]
15. S6K Promotes Dopaminergic Neuronal Differentiation Through PI3K/Akt/mTOR-Dependent Signaling Pathways in Human Neural Stem Cells.
Lee JE; Lim MS; Park JH; Park CH; Koh HC
Mol Neurobiol; 2016 Aug; 53(6):3771-3782. PubMed ID: 26143260
[TBL] [Abstract][Full Text] [Related]
16. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
Dent P; Booth L; Poklepovic A; Kirkwood JM
Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
[TBL] [Abstract][Full Text] [Related]
17. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib.
Dent P; Booth L; Poklepovic A; Von Hoff D; Martinez J; Zhou Y; Hancock JF
Biochem Pharmacol; 2021 Aug; 190():114642. PubMed ID: 34077739
[TBL] [Abstract][Full Text] [Related]
19. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
20. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
